Von Willebrand Factor as a Biomarker for Liver Disease - An Update

被引:9
作者
Elhence, Anshuman [1 ]
Shalimar [2 ]
机构
[1] All India Inst Med Sci, NCI, Dept Gastroenterol, New Delhi, India
[2] All India Inst Med Sci, Dept Gastroenterol & Human Nutr, New Delhi, India
关键词
vWF; hepatocellular carcinoma; portal hypertension; acute liver failure; acute-on-chronic liver failure; PORTAL-VEIN THROMBOSIS; FACTOR ANTIGEN; PROCOAGULANT IMBALANCE; NONINVASIVE PREDICTOR; ESOPHAGEAL-VARICES; PLASMA-LEVELS; HEPATITIS-B; CIRRHOSIS; ADAMTS13; HYPERTENSION;
D O I
10.1016/j.jceh.2023.05.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The von Willebrand factor (vWF) is best known for its role in the hemostatic pathway, aiding platelet adhesion and aggregation, as well as circulating along with coagulation factor VIII, prolonging its half-life. However, vWF is more than a hemostatic protein and is a marker of endothelial dysfunction in patients with cirrhosis. The levels of vWF increase progressively as cirrhosis progresses. Despite its qualitative defects, it can support and carry out its hemostatic role and contribute to a pro-coagulant disbalance. Moreover, it has been shown to be a good noninvasive marker for predicting clinically significant portal hypertension (CSPH). The vWF has been shown to predict decompensation and mortality among cirrhosis patients independently of the stage of liver disease and severity of portal hypertension. Increased vWF levels in the setting of endothelial injury predict bacterial translocation and systemic inflammation. The vWF-to-thrombocyte ratio (VITRO) score adds to the diagnostic ability of vWF alone in detecting CSPH non-invasively. Not only have vWF levels been shown to help predict the risk of hepatocellular carcinoma (HCC) among cirrhosis patients, but they also predict the risk of complications postresection for HCC and response to systemic therapies. vWF-induced portal microthrombi have been purported to contribute to the pathogenesis of acute liver failure progression as well as non-cirrhotic portal hypertension. The prospect of modulation of vWF levels using drugs such as non-selective beta-blockers, statins, anticoagulants, and non-absorbable antibiotics and its use as a predictive biomarker for the response to these drugs needs to be explored.
引用
收藏
页码:1047 / 1060
页数:14
相关论文
共 64 条
  • [1] Platelet physiology and thrombosis
    Andrews, RK
    Berndt, MC
    [J]. THROMBOSIS RESEARCH, 2004, 114 (5-6) : 447 - 453
  • [2] [Anonymous], 2020, EMJ Hepatol
  • [3] VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors
    Dasgupta, Suryasarathi
    Repesse, Yohann
    Bayry, Jagadeesh
    Navarrete, Ana-Maria
    Wootla, Bharath
    Delignat, Sandrine
    Irinopoulou, Theano
    Kamate, Caroline
    Saint-Remy, Jean-Marie
    Jacquemin, Marc
    Lenting, Peter J.
    Borel-Derlon, Annie
    Kaveri, Srinivas V.
    Lacroix-Desmazes, Sebastien
    [J]. BLOOD, 2007, 109 (02) : 610 - 612
  • [4] Baveno VII - Renewing consensus in portal hypertension
    de Franchis, Roberto
    Bosch, Jaime
    Garcia-Tsao, Guadalupe
    Reiberger, Thomas
    Ripoll, Cristina
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (04) : 959 - 974
  • [5] VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure
    Driever, Ellen G.
    Stravitz, R. Todd
    Zhang, Jingwen
    Adelmeijer, Jelle
    Durkalski, Valerie
    Lee, William M.
    Lisman, Ton
    [J]. HEPATOLOGY, 2021, 73 (05) : 1882 - 1891
  • [6] Systematic review: role of elevated plasma von-Willebrand factor as predictor of mortality in patients with chronic liver disease
    Eidelberg, Andrew
    Kirubakaran, Richard
    Nair, Sukesh Chandran
    Eapen, Chundamannil Eapen
    Elias, Elwyn
    Goel, Ashish
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (10) : 1184 - 1191
  • [7] Role of plasma von Willebrand factor antigen in prediction of esophageal varices in pediatric and adolescent patients with portal hypertension
    El Shazli, Lerine B.
    Ragab, Dina A.
    Abdelhady, Karim A.
    Abdelaziz, Asmaa W.
    [J]. EGYPTIAN LIVER JOURNAL, 2021, 11 (01)
  • [8] El-Toukhy N., 2019, Afro-Egyptian Journal of Infectious and Endemic Diseases, V9, P67, DOI [10.21608/aeji.2019.29119, DOI 10.21608/AEJI.2019.29119]
  • [9] Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis
    Ferlitsch, Monika
    Reiberger, Thomas
    Hoke, Matthias
    Salzl, Petra
    Schwengerer, Bernadette
    Ulbrich, Gregor
    Payer, Berit Anna
    Trauner, Michael
    Peck-Radosavljevic, Markus
    Ferlitsch, Arnulf
    [J]. HEPATOLOGY, 2012, 56 (04) : 1439 - 1447
  • [10] High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: Relationship to endotoxemia
    Ferro, D
    Quintarelli, C
    Lattuada, A
    Leo, R
    Alessandroni, M
    Mannucci, PM
    Violi, F
    [J]. HEPATOLOGY, 1996, 23 (06) : 1377 - 1383